Program
HRS-5635
A development code. Also written as “HRS-5635 Injection”, “HRS-5635 Injection (low dose) and Peg-IFN-α” and “HRS-5635 Injection (high dose) and Peg-IFN-α”.
In Jiangsu HengRui Medicine's pipeline, HBV siRNA
. Its studies are mostly in Hepatitis B, Chronic, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 33 open or running | phase 3since May 19, 2026 | Mar 29, 2023 | Jun 2028phase 3 · NCT07606950 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-5635
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 29, 2023First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT05808374 · 85 planned · China
- May 17, 2024Phase 2 study in Hepatitis B, ChronicNCT06425341 · 369 planned · China
- May 19, 2026Phase 3 study in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis BPhase 3 reachedNCT07606950 · 540 planned · China
Ahead
- Jun 2028Primary completion: phase 3 study in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis BNCT07606950
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“HBV siRNA”the company's pipeline, read by Claude · source
“This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and immunogenicity of HRS-5635 injection as compared to the placebo arm in nucleos(t)ide analogue-suppressed HBeAg-negative patients with chronic hepatitis B.”study summary, read by Claude · the study
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07606950Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B · China | 3 | Recruiting | Jun 2028 | 540 |
| NCT06425341Hepatitis B, Chronic · China | 2 | Recruiting | Aug 30, 2026 | 369 |
| NCT05808374Hepatitis B, Chronic · China | 1 | Recruiting | May 31, 2024 | 85 |
How it is read
Names in the registry
- “HRS-5635 Injection”, 6 entries
- “HRS-5635”, 3 entries
- “HRS-5635 Injection (low dose) and Peg-IFN-α”, 1 entry
- “HRS-5635 Injection (high dose) and Peg-IFN-α”, 1 entry
- “HRS-5635 Injection with Peg-IFN-α”, 1 entry
Codes read as this program: HRS5635.
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.